{"doc_type":"other","party_a_name":"Marv Enterprises, LLC","party_b_name":"Premier Biomedical, Inc.","effective_date":"2020-05-12","term_length":null,"governing_law":"Commonwealth of Pennsylvania","termination_notice_days":null,"liability_cap":"No explicit liability cap stated in provided excerpts","non_solicit_clause_present":false,"data_transfer_outside_uk_eu":"unknown","risk_level":"high","risk_explanation":"The agreement appears to be an intellectual property/licensing and joint venture arrangement with significant payment and royalty obligations (including references to payments up to $40,000,000) and reversion of exclusive license rights upon non-payment. The excerpts do not show a clear limitation of liability, which increases exposure. It also includes broad confidentiality obligations without clear carve-outs tailored to a typical SaaS relationship, making compliance and dispute risk higher."}